NAFLD was diagnosed in 38.7% (n = 305) of participants and elevated ALT was observed in 24.9% (n = 196) (2 subjects with missing data), whereas 14.2% (n = 112) had both NAFLD and elevated ALT. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.